Evidence map›Paper›PMID 28167050›Full record

ReviewBiochimica et biophysica acta. Reviews on cancer2017

Changing mutational and adaptive landscapes and the genesis of cancer.

L Alexander Liggett, James DeGregori

Open access · greenAbstract readReview
In one paragraph

Review in Biochimica et biophysica acta. Reviews on cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Relationship between Urban Green Spaces and Cancer: A Scoping Review.International journal of environmental research and public health · 2021
    Article
  15. Plasma Metabolome Signature Indicative ofFrontiers in oncology · 2021
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

L Alexander LiggettDepartment of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, CO 80045, United States.
James DeGregoriDepartment of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, CO 80045, United States; Integrated Department of Immunology, University of Colorado School of Medicine, Aurora, CO 80045, United States; Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, United States; Department of Medicine, Section of Hematology, University of Colorado School of Medicine, Aurora, CO 80045, United States. Electronic address: James.DeGregori@ucdenver.edu.
University of Colorado Denver · US

Funding

Aging-associated alterations in adaptive landscapes and the evolution of leukemiaR01CA180175 · NCI · UNIVERSITY OF COLORADO DENVER · PI DEGREGORI, JAMES V · 2013 to 2018
$1.8M
Nrf2-mediated impaired hematopoietic stem cell fitness following irradiationR21CA179501 · NCI · UNIVERSITY OF COLORADO DENVER · PI DEGREGORI, JAMES V · 2015 to 2016
$372k
The Role of Trisomy 21 in Hematopoiesis and LeukemogenesisF31CA196231 · NCI · UNIVERSITY OF COLORADO DENVER · PI LIGGETT, LUTHER ALEXANDER · 2015 to 2018
$121k
NCI NIH HHS F31 CA196231NCI NIH HHS R01 CA180175NCI NIH HHS R21 CA179501
6 · The paper itself

Abstract

By the time the process of oncogenesis has produced an advanced cancer, tumor cells have undergone extensive evolution. The cellular phenotypes resulting from this evolution have been well studied, and include accelerated growth rates, apoptosis resistance, immortality, invasiveness, and immune evasion. Yet with all of our current knowledge of tumor biology, the details of early oncogenesis have been difficult to observe and understand. Where different oncogenic mutations may work together to enhance the survival of a tumor cell, in isolation they are often pro-apoptotic, pro-differentiative or pro-senescent, and therefore often, somewhat paradoxically, disadvantageous to a cell. It is also becoming clear that somatic mutations, including those in known oncogenic drivers, are common in tissues starting at a young age. These observations raise the question: how do we largely avoid cancer for most of our lives? Here we propose that evolutionary forces can help explain this paradox. As humans and other organisms age or experience external insults such as radiation or smoking, the structure and function of tissues progressively degrade, resulting in altered stem cell niche microenvironments. As tissue integrity declines, it becomes less capable of supporting and maintaining resident stem cells. These stem cells then find themselves in a microenvironment to which they are poorly adapted, providing a competitive advantage to those cells that can restore their functionality and fitness through mutations or epigenetic changes. The resulting oncogenic clonal expansions then increase the odds of further cancer progression. Understanding how the causes of cancer, such as aging or smoking, affect tissue microenvironments to control the impact of mutations on somatic cell fitness can help reconcile the discrepancy between marked mutation accumulation starting early in life and the somatic evolution that leads to cancer at advanced ages or following carcinogenic insults. This article is part of a Special Issue entitled: Evolutionary principles - heterogeneity in cancer?, edited by Dr. Robert A. Gatenby.

Indexed as

Evolution, MolecularGenetic FitnessMutationAdaptation, PhysiologicalAnimalsAntineoplastic AgentsBiomarkers, TumorCell Transformation, NeoplasticDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHeredityHumansModels, GeneticNeoplasmsPedigreeAntineoplastic AgentsBiomarkers, TumorFitness landscapesMicroenvironmentMutationOncogenesisSomatic cell evolution

Identifiers

PMID28167050
PMCPMC5557501
OpenAlexW2583411830

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.